One of our programs, GD2 GITRL CAR project, was adopted as Strengthening Program for the Pharmaceutical Startup Ecosystem Initiative 2024 by Japan Agency for Medical Research and Development (AMED) on June 14, and it was on the web on the same day (https://www.amed.go.jp/koubo/19/02/1902C_00047.html). The title is “Research and Development of a Novel CAR-T Therapy, incorporating GITRL, on GD2 Positive Refractory Solid Tumors”.
(Reference)
About GD2:
GD2 is a glycolipid predominantly expressed on the surface of nerve cells, confirmed to be excessively expressed in various cancers, including neuroblastoma, a type of pediatric cancer, as well as triple negative breast cancer and melanoma.
Comments